Researcher/postdoc position in CAR T cells and antibody drug conjugates

at  Oslo universitetssykehus

Researcher/postdoc position in CAR T cells and antibody drug conjugates
Institute for Cancer Research, Department of Cancer Immunology
Apply for position
(in new tab)
About the position
A position as Researcher/postdoc is available for 2 years, with possibility for extension, from 15.09.2024, in the research group of Prof. Jon Amund Kyte at Dept. of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital (OUH).
The researcher will work in team with other members of the Kyte group, which has 15 members with research expertise in immunology, molecular biology and medicine. Dr. Kyte is also Head of Department for Clinical Cancer Research (www.phase1.no) and has initiated and lead several immunotherapy trials. We are currently moving one of the CAR T cell products developed in our research group into clinical testing.
OUH is Norway’s largest hospital and medical research institution, and is accredited as a Comprehensive Cancer Center by the Organization of European Cancer Institutes. OUH has a particularly strong research profile in cell therapy (ous-research.no/strat-cell), a newly established core facility for advanced cell therapy and a proven record in bringing novel immunotherapy ideas from preclinical development into clinical trials.
Research description:
The Kyte Group has developed several tumor-targeting chimeric antigen receptors (CARs) and other constructs for T cell therapy, as well as tumor targeting antibodies. The successful applicant will work on a new project called “CAR360”, for development of personalized T cell therapy countering tumor escape in treatment refractory solid cancers. This includes approaches countering immune suppression and the targeting of multiple antigens and tumor subpopulations. The project will make use of proprietary constructs developed in the group. The successful applicant will also work on the development of therapy with bispecific antibodies and antibody-drug conjugates (ADC) targeting tumor-specific antigens. The required methods have been established.
Oslo University Hospital is a workplace with great diversity. We believe this is absolutely crucial to solving the tasks required of us. We therefore want this diversity to be reflected among the applicants for our positions and encourage everyone to apply regardless of who you are and what background you have.
Key information
Application deadline:
01.09.2024
Employer:

Please refer the Job description for details